MDM2基因SNP309多態性與白血病易感性關系的Meta分析_《中國循證醫學雜志》

作者：

鄭沁 , 劉華 , 曾婷婷 , 葉遠馨 , 蔣能剛 ,  粟軍

四川大學華西醫院實驗醫學科（成都 610041）;

關鍵詞：

MDM2 白血病單核苷酸多態性系統評價 Meta分析病例-對照研究

DOI：

10.7507/1672-2531.20130030

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　系統評價小鼠雙微體基因2（murine double minute 2，MDM2）啟動子309位點單核苷酸多態性（single nucleotide polymorphism，SNP309）與白血病易感性的關系。
方法　計算機檢索Ovid、EBSCO、PubMed、CNKI、CBM、VIP及WanFang Data，搜集相關病例-對照研究，檢索時限為1990年1月～2012年6月。按納入與排除標準篩選文獻、提取資料并評價納入研究的方法學質量后，采用RevMan 5.0、Stata 10.0軟件進行Meta分析，計算合并OR值及其95%CI，并進行敏感性分析及發表偏倚評估。
結果　共納入8篇文獻9個研究，累計病例1 821例，對照5 642例。Meta分析結果顯示：攜帶G等位基因者對于T等位基因者，白血病易感性增加［OR=1.26，95%CI（1.08，1.46），P=0.003］；基因型為GG的人群白血病發病風險高于基因型為TT的人群［OR=1.46，95%CI（1.02，2.10），P=0.04］；隱性模型中亞洲人GG純合子基因型人群白血病發病風險高于GT+TT基因型人群［OR=2.00，95%CI（1.37，2.92），P=0.000 3］。未見明顯發表偏倚。
結論　MDM2基因SNP309多態性與白血病易感性相關，等位基因G可能是白血病易感的危險因素。

引用本文： 鄭沁,劉華,曾婷婷,葉遠馨,蔣能剛,粟軍. MDM2基因SNP309多態性與白血病易感性關系的Meta分析. 中國循證醫學雜志, 2013, 13(2): 170-175. doi: 10.7507/1672-2531.20130030 復制

1.	Satoh Y, Matsumura I, Tanaka H, et al. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. Leukemia, 2012, 26(2): 303-311.
2.	Vogelstein B, Lane D, Levine AJ. Surfing the P53 network. Nature, 2000, 408(6810): 307-310.
3.	Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol, 2003, 13(1): 49-58.
4.	Bond GL, Hu W, Bond EE, et al. A single nueleotide polymorphism in the MDM2 promoter attenuates the P53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 2004, 119(5): 591-602.
5.	吳曉梅, 時玥, 時景璞, 等. 中國漢族人群腦出血患者血管緊張素轉換酶基因插入/缺失多態性的Meta分析. 中國循證醫學雜志, 2009, 9(12): 1323-1327.
6.	Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood, 2008, 112(3): 741-749.
7.	Zenz T, Habe S, Benner A, et al. The MDM2-309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica, 2008, 93(7): 1111-1113.
8.	Phang BH, Linn YC, Li H, et al. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer, 2008, 44(5): 760-766.
9.	Chen YL, Chang YS, Chang JG, et al. Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal Bioanal Chem, 2009, 394(5): 1291-1297.
10.	Xiong X, Wang M, Wang L, et al. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res, 2009, 33(11):1454- 1458.
11.	Do TN, Ucisik-Akkaya E, Davis CF, et al. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet, 2009, 195(1): 31-36.
12.	Phillips CL, Gerbing R, Alonzo T, et al. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer, 2010, 55(2): 248- 253.
13.	Dong HJ, Fang C, Fan L, et al. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. Int J Cancer, 2012, 130(9): 2054-2061.
14.	Yi ZH. A meta analysis on expression of cyclooxygenase-2 in gastric carcinoma. Bulletin of Chinese Cancer, 2007, 16(5): 365-367.
15.	Dharel N, Kato N, Muroyama R, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res, 2006,12(16): 4867-4871.
16.	Onat OE, Tez M, Ozcelik T, et al. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res, 2008, 26(5A): 3473-3475.
17.	Hong Y, Miao X, Zhang X, et al. The role of p53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res, 2005, 65(20): 9582-9587.

1. Satoh Y, Matsumura I, Tanaka H, et al. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. Leukemia, 2012, 26(2): 303-311.
2. Vogelstein B, Lane D, Levine AJ. Surfing the P53 network. Nature, 2000, 408(6810): 307-310.
3. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol, 2003, 13(1): 49-58.
4. Bond GL, Hu W, Bond EE, et al. A single nueleotide polymorphism in the MDM2 promoter attenuates the P53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 2004, 119(5): 591-602.
5. 吳曉梅, 時玥, 時景璞, 等. 中國漢族人群腦出血患者血管緊張素轉換酶基因插入/缺失多態性的Meta分析. 中國循證醫學雜志, 2009, 9(12): 1323-1327.
6. Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood, 2008, 112(3): 741-749.
7. Zenz T, Habe S, Benner A, et al. The MDM2-309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica, 2008, 93(7): 1111-1113.
8. Phang BH, Linn YC, Li H, et al. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer, 2008, 44(5): 760-766.
9. Chen YL, Chang YS, Chang JG, et al. Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal Bioanal Chem, 2009, 394(5): 1291-1297.
10. Xiong X, Wang M, Wang L, et al. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res, 2009, 33(11):1454- 1458.
11. Do TN, Ucisik-Akkaya E, Davis CF, et al. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet, 2009, 195(1): 31-36.
12. Phillips CL, Gerbing R, Alonzo T, et al. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer, 2010, 55(2): 248- 253.
13. Dong HJ, Fang C, Fan L, et al. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. Int J Cancer, 2012, 130(9): 2054-2061.
14. Yi ZH. A meta analysis on expression of cyclooxygenase-2 in gastric carcinoma. Bulletin of Chinese Cancer, 2007, 16(5): 365-367.
15. Dharel N, Kato N, Muroyama R, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res, 2006,12(16): 4867-4871.
16. Onat OE, Tez M, Ozcelik T, et al. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res, 2008, 26(5A): 3473-3475.
17. Hong Y, Miao X, Zhang X, et al. The role of p53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res, 2005, 65(20): 9582-9587.

《中國循證醫學雜志》

MDM2基因SNP309多態性與白血病易感性關系的Meta分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《中國循證醫學雜志》

MDM2基因SNP309多態性與白血病易感性關系的Meta分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料